Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""B-cell"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 1814
Tytuł:
Dynamic hydrogen peroxide levels reveal a rate-dependent sensitivity in B-cell lymphoma signaling.
Autorzy:
Witmond M; Institute for Molecules and Materials (IMM), Radboud University Nijmegen, Nijmegen, The Netherlands.
Keizer E; Institute for Molecules and Materials (IMM), Radboud University Nijmegen, Nijmegen, The Netherlands.
Kiffen B; Institute for Molecules and Materials (IMM), Radboud University Nijmegen, Nijmegen, The Netherlands.
Huck WTS; Institute for Molecules and Materials (IMM), Radboud University Nijmegen, Nijmegen, The Netherlands. .
van Buggenum JAGL; Institute for Molecules and Materials (IMM), Radboud University Nijmegen, Nijmegen, The Netherlands. .; Single Cell Discoveries (SCD), Utrecht, The Netherlands. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 21; Vol. 14 (1), pp. 4265. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:
Journal Article
MeSH Terms:
Hydrogen Peroxide*
Lymphoma, Large B-Cell, Diffuse*/pathology
Humans ; Signal Transduction ; Phosphorylation ; Receptors, Antigen, B-Cell/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term monitoring of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the MALT1 gene.
Autorzy:
Iwamuro M; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. .
Takenaka R; Department of Internal Medicine, Tsuyama Chuo Hospital, Tsuyama, 708‑0841, Japan.
Miyahara K; Department of Internal Medicine, Hiroshima City Hospital, Hiroshima, 730-8518, Japan.
Okanoue S; Department of Gastroenterology, Mitoyo General Hospital, Kanonji, 769‑1695, Japan.
Yoshioka M; Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, 700‑8511, Japan.
Sakaguchi C; Department of Gastroenterology, Shikoku Cancer Center, Matsuyama, 791-0280, Japan.
Yamamoto K; Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, 760‑8557, Japan.
Kawai Y; Department of Gastroenterology, Onomichi Municipal Hospital, Onomichi, 722‑8503, Japan.
Toyokawa T; Department of Gastroenterology, Fukuyama Medical Center, Fukuyama, 720‑8520, Japan.
Tanaka T; Department of Pathology, Okayama University Hospital, Okayama, 700-8558, Japan.
Otsuka M; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 29; Vol. 14 (1), pp. 4953. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Lymphoma, B-Cell, Marginal Zone*/genetics
Lymphoma, B-Cell, Marginal Zone*/pathology
Lymphoma, Non-Hodgkin*
Stomach Neoplasms*
Humans ; In Situ Hybridization, Fluorescence ; Retrospective Studies ; Neoplasm Recurrence, Local/genetics ; Translocation, Genetic ; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein/genetics
SCR Disease Name:
Familial primary gastric lymphoma
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Deep learning assists in acute leukemia detection and cell classification via flow cytometry using the acute leukemia orientation tube.
Autorzy:
Cheng FM; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Lo SC; Artificial Intelligence Center, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Lin CC; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Lo WJ; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Chien SY; Artificial Intelligence Center, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Sun TH; Artificial Intelligence Center, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan.
Hsu KC; Artificial Intelligence Center, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan. .; School of Medicine, China Medical University, Taichung, 404, Taiwan. .; Neuroscience and Brain Disease Center, China Medical University, Taichung, 404, Taiwan. .; Department of Neurology, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Apr 09; Vol. 14 (1), pp. 8350. Date of Electronic Publication: 2024 Apr 09.
Typ publikacji:
Journal Article
MeSH Terms:
Deep Learning*
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/pathology
Humans ; Retrospective Studies ; Flow Cytometry/methods ; Artificial Intelligence ; Acute Disease ; Immunophenotyping
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Declining incidence and improving survival of ocular and orbital lymphomas in the US between 1995 and 2018.
Autorzy:
Alfaar AS; Medical Neuroscience PhD Program, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-University, 10117, Berlin, Germany. .; Department of Ophthalmology, The Royal Liverpool University Hospital, Liverpool, UK. .
Yousef YA; Department of Surgery/Ophthalmology, King Hussein Cancer Center, Amman, Jordan.
W Wilson M; St. Jude Children's Research Hospital, Memphis, TN, USA.; Department of Ophthalmology, University of Tennesse Health Science Center, Hamilton Eye Institute, Memphis, TN, USA.
Hassanain O; Research Department, Children's Cancer Hospital -Egypt, 57357, Cairo, Egypt.
Kakkassery V; Ophthalmology Department, University Hospital of Schleswig-Holstein, Lübeck, Germany.; Ophthalmology Department, Klinikum Chemnitz, Chemnitz, Germany.
Moustafa M; Ophthalmology Department, University Hospital Hairmyres, East Kilbride, Scotland, UK.
Kunbaz A; Ophthalmology Department, Istanbul Medeniyet University, Istanbul, Turkey.
Esmael A; Ophthalmology Department, Cairo University, Cairo, Egypt.
Strauß O; Experimental Ophthalmology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-University, 10117, Berlin, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Apr 03; Vol. 14 (1), pp. 7886. Date of Electronic Publication: 2024 Apr 03.
Typ publikacji:
Journal Article
MeSH Terms:
Orbital Neoplasms*/epidemiology
Orbital Neoplasms*/pathology
Eye Neoplasms*/epidemiology
Lymphoma, B-Cell, Marginal Zone*/pathology
Lymphoma*
Humans ; United States/epidemiology ; Incidence
SCR Disease Name:
Orbital lymphoma
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lysine demethylase LSD1 is associated with stemness in EBV-positive B cell lymphoma.
Autorzy:
Kim JH; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, 06351, Korea.
Park C; Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Korea.
Kim WS; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, 06351, Korea. .; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Seoul, 06351, Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 21; Vol. 14 (1), pp. 6764. Date of Electronic Publication: 2024 Mar 21.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma*/genetics
Lymphoma, B-Cell*/genetics
Humans ; Herpesvirus 4, Human/genetics ; Lysine/metabolism ; Epigenesis, Genetic ; Histone Demethylases/metabolism ; Doxorubicin/pharmacology ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting autophagy as a therapeutic strategy in pediatric acute lymphoblastic leukemia.
Autorzy:
Bwanika HC; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.
Leo IR; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.; Science for Life Laboratory, Solna, Sweden.
Struyf N; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.; Science for Life Laboratory, Solna, Sweden.
Talanti A; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.
Aswad L; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.; Science for Life Laboratory, Solna, Sweden.
Konnur A; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.
Björklund AC; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Huddinge, Sweden.
Heyman M; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Rassidakis G; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.
Erkers T; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.; Science for Life Laboratory, Solna, Sweden.
Seashore-Ludlow B; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.; Science for Life Laboratory, Solna, Sweden.
Jafari R; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden.; Science for Life Laboratory, Solna, Sweden.
Pokrovskaja Tamm K; Department of Oncology and Pathology, Karolinska Institutet, Akademiska stråket 1, BioClinicum J6:14, 17164, Solna, Sweden. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 18; Vol. 14 (1), pp. 4000. Date of Electronic Publication: 2024 Feb 18.
Typ publikacji:
Journal Article
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Child ; Humans ; Autophagy ; Cell Line ; Glucocorticoids/therapeutic use ; Cell Line, Tumor ; Apoptosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus.
Autorzy:
Ortiz-Aljaro P; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), 41013, Seville, Spain.
Montes-Cano MA; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), 41013, Seville, Spain.
García-Lozano JR; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), 41013, Seville, Spain.
Aquino V; Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, 41013, Seville, Spain.
Carmona R; Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, 41013, Seville, Spain.; Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocío, Seville, Spain.
Perez-Florido J; Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, 41013, Seville, Spain.; Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocío, Seville, Spain.; Computational Systems Medicine, Institute of Biomedicine of Seville (IBIS), Hospital Virgen del Rocio, Seville, Spain.
García-Hernández FJ; Department of Internal Medicine, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), 41013, Seville, Spain.
Dopazo J; Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, 41013, Seville, Spain.; Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocío, Seville, Spain.; Computational Systems Medicine, Institute of Biomedicine of Seville (IBIS), Hospital Virgen del Rocio, Seville, Spain.; Functional Genomics Node, FPS/ELIXIR-es, Hospital Virgen del Rocío, Seville, Spain.
González-Escribano MF; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), 41013, Seville, Spain. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jul 02; Vol. 12 (1), pp. 11219. Date of Electronic Publication: 2022 Jul 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
B-Cell Activating Factor*/genetics
B-Cell Activating Factor*/metabolism
Lupus Erythematosus, Systemic*/genetics
Lupus Erythematosus, Systemic*/metabolism
Lupus Nephritis*/genetics
Lupus Nephritis*/metabolism
Tumor Necrosis Factor Ligand Superfamily Member 13*/genetics
Tumor Necrosis Factor Ligand Superfamily Member 13*/metabolism
Adolescent ; Adult ; B-Cell Maturation Antigen/genetics ; B-Cell Maturation Antigen/metabolism ; Case-Control Studies ; Female ; Humans ; Middle Aged ; Protein Isoforms ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.
Autorzy:
Goodstal SM; Research Unit Oncology, EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA, 01821, USA. .
Lin J; Research Unit Oncology, EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA, 01821, USA.
Crandall T; Research Unit Oncology, EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA, 01821, USA.
Crowley L; Research Unit Oncology, EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA, 01821, USA.
Bender AT; Research Unit Immunology, EMD Serono Research and Development Institute, Inc., Billerica, MA, 01821, USA.
Pereira A; Research Unit Immunology, EMD Serono Research and Development Institute, Inc., Billerica, MA, 01821, USA.
Soloviev M; Protein Engineering Antibody Technologies, EMD Serono Research and Development Institute, Inc., Billerica, MA, 01821, USA.
Wesolowski JS; Protein Engineering Antibody Technologies, EMD Serono Research and Development Institute, Inc., Billerica, MA, 01821, USA.
Iadevaia R; Research Unit Oncology, EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA, 01821, USA.
Schelhorn SE; Oncology Bioinformatics Quantitative Pharmacology and Drug Disposition (QPD) Biopharma, Merck KGaA, 64293, Darmstadt, Germany.
Ross E; Oncology Bioinformatics Quantitative Pharmacology and Drug Disposition (QPD) Biopharma, Merck KGaA, 64293, Darmstadt, Germany.
Morandi F; Discovery and Development Technologies, EMD Serono Research and Development Institute, Inc., Billerica, MA, 01821, USA.
Ma J; Research Unit Oncology, EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA, 01821, USA.
Clark A; Research Unit Oncology, EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA, 01821, USA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 21; Vol. 13 (1), pp. 20412. Date of Electronic Publication: 2023 Nov 21.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Lymphoma, Large B-Cell, Diffuse*/pathology
Humans ; B-Lymphocytes/metabolism ; Agammaglobulinaemia Tyrosine Kinase ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Plasma-derived exosomal miR-326, a prognostic biomarker and novel candidate for treatment of drug resistant pediatric acute lymphoblastic leukemia.
Autorzy:
Saffari N; Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Hezar jarib Street, Isfahan, 81746-73441, Iran.
Rahgozar S; Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Hezar jarib Street, Isfahan, 81746-73441, Iran. .
Faraji E; Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Hezar jarib Street, Isfahan, 81746-73441, Iran.
Sahin F; Department of Genetics and Bioengineering, Yeditepe University, Atasehir, 34755, Istanbul, Turkey.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 06; Vol. 14 (1), pp. 691. Date of Electronic Publication: 2024 Jan 06.
Typ publikacji:
Journal Article
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*
MicroRNAs*/genetics
Humans ; Child ; Prognosis ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.
Autorzy:
Deng M; Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, China.; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361102, China.
Tan J; Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, China.; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361102, China.
Fan Z; Department of Hematology, Dongguan People's Hospital, Dongguan, 523000, China.
Pham LV; Phamacyclics, an Abbvie Company, San Francisco, CA, USA.
Zhu F; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Fang X; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Zhao H; Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, China. zhaohaijun_.; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361102, China. zhaohaijun_.; Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, No.55, Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. zhaohaijun_.
Young K; Division of Hematopathology and Department of Pathology, Duke University Medical Center, Durham, NC, USA. .
Xu B; Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, China. .; Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361102, China. .; Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, No.55, Zhenhai Road, Siming District, Xiamen, 361003, Fujian, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 29; Vol. 13 (1), pp. 18554. Date of Electronic Publication: 2023 Oct 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, B-Cell*/genetics
Lymphoma, Large B-Cell, Diffuse*/genetics
Humans ; Down-Regulation ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-myc/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia.
Autorzy:
Vitale C; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Griggio V; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Todaro M; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Riganti C; Department of Oncology, University of Torino, 10126, Turin, Italy.
Jones R; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Boccellato E; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Perutelli F; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Arruga F; Department of Medical Sciences, University of Torino, 10126, Turin, Italy.
Vaisitti T; Department of Medical Sciences, University of Torino, 10126, Turin, Italy.
Efremov DG; Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, 34149, Trieste, Italy.
Deaglio S; Department of Medical Sciences, University of Torino, 10126, Turin, Italy.
Landesman Y; Karyopharm Therapeutics, Newton, MA, 024559, USA.
Bruno B; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Coscia M; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy. .; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 07; Vol. 13 (1), pp. 16950. Date of Electronic Publication: 2023 Oct 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Animals ; Mice ; Cell Line, Tumor ; Hydrazines/pharmacology ; Hydrazines/therapeutic use ; Drug Combinations ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients.
Autorzy:
Ferrández MC; Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. .; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands. .
Golla SSV; Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Eertink JJ; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
de Vries BM; Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Lugtenburg PJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Wiegers SE; Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Zwezerijnen GJC; Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Pieplenbosch S; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Kurch L; Department of Nuclear Medicine, Clinic and Polyclinic for Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Hüttmann A; Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Hanoun C; Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Dührsen U; Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
de Vet HCW; Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Department of Methodology, Amsterdam Public Health Research Institute, Methodology, Amsterdam, The Netherlands.
Zijlstra JM; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Boellaard R; Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Pokaż więcej
Corporate Authors:
PETRA
Źródło:
Scientific reports [Sci Rep] 2023 Aug 12; Vol. 13 (1), pp. 13111. Date of Electronic Publication: 2023 Aug 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Fluorodeoxyglucose F18*
Lymphoma, Large B-Cell, Diffuse*/diagnostic imaging
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/metabolism
Humans ; Artificial Intelligence ; Positron Emission Tomography Computed Tomography/methods ; Positron-Emission Tomography ; Prognosis ; Prospective Studies ; Retrospective Studies ; Tomography, X-Ray Computed ; Treatment Outcome ; Clinical Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma.
Autorzy:
Min GJ; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Jeon YW; Department of Hematology, Yeouido St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, Republic of Korea.
Kim TY; Department of Hematology, Yeouido St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, Republic of Korea.
Kwag D; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Kim BS; Department of Hematology, Eunpyeong St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, 1021, Tongil Ro, Eunpyeong-gu, Seoul, Republic of Korea.
Lee J; Department of Hematology, Eunpyeong St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, 1021, Tongil Ro, Eunpyeong-gu, Seoul, Republic of Korea.
Lee JH; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Park SS; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Park S; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Yoon JH; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Lee SE; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Cho BS; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Eom KS; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Kim YJ; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Lee S; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Kim HJ; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Min CK; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Lee JW; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.
Cho SG; Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 15; Vol. 13 (1), pp. 17496. Date of Electronic Publication: 2023 Oct 15.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Lymphoma, Non-Hodgkin*/therapy
Lymphoma, Large B-Cell, Diffuse*/therapy
Humans ; Disease-Free Survival ; Neoplasm Recurrence, Local/therapy ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms.
Autorzy:
Fernández-Garnacho EM; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.
Nadeu F; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Martín S; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.
Mozas P; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Rivero A; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Delgado J; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Giné E; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
López-Guillermo A; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Duran-Ferrer M; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.
Salaverria I; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
López C; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Beà S; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Demajo S; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.
Jares P; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Puente XS; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; University of Oviedo, Oviedo, Spain.
Martín-Subero JI; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Campo E; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Hernández L; Lymphoid Neoplasm Program, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centre Esther Koplowitz (CEK), Rosselló 153, 08036, Barcelona, Spain. .; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 06; Vol. 13 (1), pp. 16839. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Lymphoma, Follicular*/genetics
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Humans ; Genes, Neoplasm ; Prognosis ; Tumor Microenvironment/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Analysis of endoplasmic reticulum stress-related gene signature for the prognosis and pattern in diffuse large B cell lymphoma.
Autorzy:
Zhang C; Department of Hematology and Rheumatology, The Affiliated Hospital of Putian University, Putian, Fujian Province, China.; The School of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian Province, China.
Lin Q; Department of Pharmacy, The Affiliated Hospital of Putian University, Putian, Fujian Province, China.; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian Province, China.
Li C; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian Province, China.
Chen Z; Department of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian Province, China.
Deng M; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian Province, China.
Weng H; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian Province, China.
Zhu X; The School of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian Province, China. .; Department of Haematology, Quanzhou First Hospital of Affiliated to Fujian Medical University, Quanzhou, Fujian Province, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Aug 25; Vol. 13 (1), pp. 13894. Date of Electronic Publication: 2023 Aug 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/genetics
Adult ; Humans ; Prognosis ; Nomograms ; Databases, Chemical ; Endoplasmic Reticulum Stress/genetics ; Tumor Microenvironment/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy.
Autorzy:
Shirouchi Y; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Nishimura N; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Mishima Y; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Ishihara Y; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Asai H; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Tamba M; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Hirano M; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Hirano K; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Teramoto Y; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Yoshida K; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan.
Takeuchi K; Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.; Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.; Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Terauchi T; Department of Nuclear Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Maruyama D; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Ariake, Koto, Tokyo, Japan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Aug 22; Vol. 13 (1), pp. 13713. Date of Electronic Publication: 2023 Aug 22.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Prognosis ; Retrospective Studies ; Patients ; Receptors, Interleukin-2
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma.
Autorzy:
Larrabeiti-Etxebarria A; Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Leioa, Spain.
Bilbao-Aldaiturriaga N; Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Leioa, Spain.; Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n, 48940, Leioa, Spain.; Pediatric Oncology Group, BioCruces Bizkaia Health Research Institute, Barakaldo, Spain.
Arzuaga-Mendez J; Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Leioa, Spain.; Hematologic Neoplasm Group, BioCruces Bizkaia Health Research Institute, Barakaldo, Spain.
Martin-Arruti M; Pathology Department, Donostia University Hospital, San Sebastián, Spain.
Cozzuto L; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Gaafar A; Pathology Department, Cruces University Hospital, Barakaldo, Spain.
Ruiz-Diaz I; Pathology Department, Donostia University Hospital, San Sebastián, Spain.
Guerra I; Pathology Department, Araba University Hospital, Vitoria, Spain.
Martin-Guerrero I; Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Leioa, Spain.; Pediatric Oncology Group, BioCruces Bizkaia Health Research Institute, Barakaldo, Spain.
Lopez-Lopez E; Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n, 48940, Leioa, Spain. .; Pediatric Oncology Group, BioCruces Bizkaia Health Research Institute, Barakaldo, Spain. .
Gutierrez-Camino A; Pediatric Oncology Group, BioCruces Bizkaia Health Research Institute, Barakaldo, Spain.; Division of Hematology-Oncology, CHU Sainte-Justine Research Center, Montreal, Canada.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jul 27; Vol. 13 (1), pp. 12159. Date of Electronic Publication: 2023 Jul 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
MicroRNAs*/genetics
MicroRNAs*/metabolism
Lymphoma, Large B-Cell, Diffuse*/diagnosis
Lymphoma, Large B-Cell, Diffuse*/genetics
Lymphoma, Large B-Cell, Diffuse*/metabolism
Humans ; Neoplasm Recurrence, Local ; Prognosis ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
Autorzy:
Nguyen TT; International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.; Department of Oncology, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
Nhu NT; International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.; Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam.
Tran VK; International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.; Department of Surgery, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
Viet-Nhi NK; International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.
Ho XD; Department of Oncology, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
Jhan MK; Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, No. 25, Wuxing St, Xinyi District, Taipei, 110, Taiwan.; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.
Chen YP; Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan.
Lin CF; Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, No. 25, Wuxing St, Xinyi District, Taipei, 110, Taiwan. .; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan. .; Core Laboratory of Immune Monitoring, Office of Research & Development, Taipei Medical University, Taipei, 110, Taiwan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jun 16; Vol. 13 (1), pp. 9775. Date of Electronic Publication: 2023 Jun 16.
Typ publikacji:
Systematic Review; Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Antineoplastic Agents*/therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Humans ; Remission Induction ; Tyrosine Kinase Inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
NCBP1 enhanced proliferation of DLBCL cells via METTL3-mediated m6A modification of c-Myc.
Autorzy:
Meng S; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.; Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, 758 Heifei Road, Qingdao, 266035, Shandong, People's Republic of China.
Xia Y; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.
Li M; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.
Wu Y; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.
Wang D; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.
Zhou Y; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.
Ma D; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.
Ye J; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.
Sun T; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China. .
Ji C; Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 May 27; Vol. 13 (1), pp. 8606. Date of Electronic Publication: 2023 May 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Methyltransferases*/genetics
Methyltransferases*/metabolism
Lymphoma, Large B-Cell, Diffuse*/genetics
Humans ; Cell Line, Tumor ; Cell Proliferation/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The inflammatory prognostic index as a potential predictor of prognosis in metastatic gastric cancer.
Autorzy:
Ozveren A; Medical Oncology Department, Internal Medicine, Izmir Private Kent Hospital, Izmir, Turkey. ahmet_.
Erdogan AP; Medical Oncology Department, Internal Medicine, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.
Ekinci F; Medical Oncology Department, Internal Medicine, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 May 12; Vol. 13 (1), pp. 7755. Date of Electronic Publication: 2023 May 12.
Typ publikacji:
Journal Article
MeSH Terms:
Stomach Neoplasms*/diagnosis
Stomach Neoplasms*/drug therapy
Carcinoma, Non-Small-Cell Lung*
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lung Neoplasms*
Splenic Neoplasms*
Humans ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Prognosis ; Disease-Free Survival ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 1814

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies